Literature DB >> 19457138

A 2-log drop in viral load at 1 month is the best predictor of sustained response in HCV patients with normal ALT: a kinetic prospective study.

P Deltenre1, V Canva, M El Nady, C François, S Castelain, S Dharancy, A Louvet, L Bocket, M Lazrek, A Hollebecque, F Wartel, J Henrion, G Duverlie, P Mathurin.   

Abstract

The most reliable predictor of a sustained virological response in patients with persistently normal ALT has not been identified. We analysed 17 patients with genotype 1 chronic HCV who underwent therapy with pegylated interferon alfa 2b and ribavirin for 48 weeks. Two patients discontinued therapy within 28 days because of side effects and the remaining 15 patients were analysed in detail. An analysis of on treatment virological response using area under the receiver operating characteristic analyses showed that a 2 log drop in HCV RNA at day 28 was the best predictor of a sustained virological response and a failure to reduce viral load by 2 logs correctly identified patients with a low (<15%) probability of achieving a sustained virological response. Introduction of this early discontinuation rule in patients with normal ALT would allow nearly half of the patients to discontinue futile therapy at an early stage.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19457138     DOI: 10.1111/j.1365-2893.2009.01100.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  3 in total

1.  Modulation of Immune Cell Subsets by Hepatitis C Virus and Antiviral Therapy in Early Virological Response HCV Genotype 4-Infected Patients with Compensated Liver Disease.

Authors:  Sahar Essa; Raja'a Al-Attiyah; Iqbal Siddique; Widad Al-Nakib
Journal:  Med Princ Pract       Date:  2020-09-23       Impact factor: 1.927

2.  Sample-to-Answer Droplet Magnetofluidic Platform for Point-of-Care Hepatitis C Viral Load Quantitation.

Authors:  Dong Jin Shin; Alexander Y Trick; Yu-Hsiang Hsieh; David L Thomas; Tza-Huei Wang
Journal:  Sci Rep       Date:  2018-06-28       Impact factor: 4.379

3.  High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b.

Authors:  Hidenori Toyoda; Takashi Kumada; Seiki Kiriyama; Makoto Tanikawa; Yasuhiro Hisanaga; Akira Kanamori; Toshifumi Tada; Takahiro Arakawa; Masashi Fujimori; Takuro Niinomi; Naoto Ando; Satoshi Yasuda; Keisuke Sakai; Jun Kimura
Journal:  J Gastroenterol       Date:  2010-10-07       Impact factor: 7.527

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.